You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output.
Click here to find out more.
| Title |
Corrigendum: Clinical efficacy, safety and tolerability of a new subcutaneous immunoglobulin 16.5% (Octanorm [Cutaquig®]) in the treatment of patients with primary immunodeficiencies
|
|---|---|
| Published in |
Frontiers in immunology, December 2022
|
| DOI | 10.3389/fimmu.2022.1110388 |
| Pubmed ID | |
| Authors |
Roger H. Kobayashi, Sudhir Gupta, Isaac Melamed, J. Fernando Mandujano, Ai Lan Kobayashi, Bruce Ritchie, Bob Geng, Thomas Prescott Atkinson, Syed Rehman, Eva Turpel-Kantor, Jiří Litzman |